Company profile: Adamas Pharma
1.1 - Company Overview
Company description
- Provider of controlled and extended-release combination therapeutics for infectious diseases and central nervous system disorders, including products for symptomatic treatment of dementia. Offerings include Qelbree for ADHD; Trokendi XR and Oxtellar XR for epilepsy and migraine prevention; and candidates SPN-830 (hypomobility in Parkinsonβs disease), SPN-820/821 (treatment-resistant depression), SPN-817 (severe epilepsy).
Products and services
- Trokendi XR: Extended-release (XR) medication used for the treatment of epilepsy and migraine prevention in central nervous system disorders, delivers extended-release administration for seizure management and migraine prophylaxis
- Oxtellar XR: Extended-release (XR) medication used for the treatment of epilepsy in central nervous system disorders, offers extended-release administration for seizure management
- SPN-830: Product candidate for the treatment of hypomobility in Parkinsonβs disease, a central nervous system disorder, designated as a development-stage therapeutic candidate
Key contacts
π
π
Financial details
π
1.2 - Competitors and similar companies to Adamas Pharma
Autobahn Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage restorative treatments for neuropsychiatric and neuroimmunologic disorders, including ABX-002 (CNS-directed TRΞ² agonist for major depressive disorder), ABX-003 (next-generation TRΞ²-selective thyromimetic in IND-enabling studies), ABX-101 (S1P receptor modulator with neuroinflammatory and neuroprotective benefits), and a brain-targeting chemistry platform for tailored CNS/peripheral drug exposure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Autobahn Therapeutics company profile β
Xanodyne
HQ: United States
Website
- Description: Provider of integrated specialty pharmaceutical products, developing and commercializing offerings in women's healthcare and pain management in the United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Xanodyne company profile β
Sooma Medical
HQ: Finland
Website
- Description: Provider of non-invasive tDCS-based brain stimulation therapies and devices for depression and chronic pain. Offers Sooma Duo, integrating a tDCS device with a digital platform for remote patient guidance and clinical management; Sooma Depression Therapy for MDD; Sooma Pain Therapy for fibromyalgia and chronic neuropathic pain; and a portable tDCS device with accessories and an online platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Sooma Medical company profile β
Liftware
HQ: United States
Website
- Description: Provider of electronic stabilizing and leveling utensil handles with interchangeable attachments (soup spoon, everyday spoon, fork, spork), designed to help people eat more easily by reducing utensil shaking for hand tremor and keeping utensils level for limited hand or arm mobility.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Liftware company profile β
Quoin Pharmaceuticals
HQ: United States
Website
- Description: Provider of pharmaceutical products under development addressing major unmet medical needs, including QRX003, a topical lotion in clinical evaluation for Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma; QRX008 for Scleroderma; QRX007 for Netherton Syndrome; and QRX004 for Epidermolysis Bullosa.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Quoin Pharmaceuticals company profile β
π
2.M&A buyers
2.1 Potential strategic acquirers in the sector
π
π
π
π
View all strategic buyers with complete profiles
Start Free Trial β
2.2 - Strategic buyer groups for Adamas Pharma
π
Buyer group 1: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 2: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 3: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial β
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Adamas Pharma
2.2 - Growth funds investing in similar companies to Adamas Pharma
π
View all growth equity funds with complete profiles
Start Free Trial β
4 - Top valuation comps for Adamas Pharma
4.2 - Public trading comparable groups for Adamas Pharma
π Unlock all public trading comparable groups with complete valuation data
Start Free Trial β